November 3, 2025 Q3 2025 Earnings Conference Call Patients can't wait for the next breakthrough in medical research. So neither will we. Doug Ingram CEO Louise Rodino-Klapac, PhD President, R&D and Technical Operations Patrick E. Moss, PharmD Executive Vice President, Chief Commercial Officer Ryan H. Wong Executive Vice President, Chief Financial Officer DILLON Living with Duchenne muscular dystrophy ©SAREPTA THERAPEUTICS, INC. 2025. ALL RIGHTS RESERVED. 1 Forward-looking statements In order to provide Sare ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading higher on Wednesday, with apparently no news to justify the movement.This week, Sarepta will present data from its gene therapy, delandistrogene moxeparvovec, for Duchenne muscular dystrophy (DMD).Sarepta presentations will include results from several studies in the delandistrogene moxeparvovec clinical development program and a real-world evidence study of pulmonary function in advanced-stage patients with Duchenne muscular dystrophy treated with ca ...